Literature DB >> 3600145

Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages.

P J Jenner, S E Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3600145     DOI： 10.5935/0305-7518.19870004

Source DB:  PubMed          Journal:  Lepr Rev        ISSN： 0305-7518            Impact factor:   0.537


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.

Authors:  B Auclair; D E Nix; R D Adam; G T James; C A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition.

Authors:  Michelle Lay Teng Ang; Siti Zarina Zainul Rahim; Zarina Zainul Rahim Siti; Guanghou Shui; Petronela Dianiškova; Jan Madacki; Wenwei Lin; Vanessa Hui Qi Koh; Julia Maria Martinez Gomez; Sukumar Sudarkodi; Anne Bendt; Markus Wenk; Katarína Mikušová; Jana Korduláková; Kevin Pethe; Sylvie Alonso
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

3.  Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.

Authors:  Hwi-Yeol Yun; Min Jung Chang; Heeyoon Jung; Vincent Chang; Qianwen Wang; Natasha Strydom; Young-Ran Yoon; Radojka M Savic
Journal:  Antimicrob Agents Chemother       Date:  2022-08-08       Impact factor: 5.938

Review 5.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.

Authors:  Henrik Bjugård Nyberg; Heather R Draper; Anthony J Garcia-Prats; Stephanie Thee; Adrie Bekker; Heather J Zar; Andrew C Hooker; H Simon Schaaf; Helen McIlleron; Anneke C Hesseling; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.938

7.  EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.

Authors:  Michelle L T Ang; Siti Z Zainul Rahim; Paola Florez de Sessions; Wenwei Lin; Vanessa Koh; Kevin Pethe; Martin L Hibberd; Sylvie Alonso
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

Review 8.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.